Pfizer announces top-line results from phase 3 trial of INLYTA® (axitinib)
17 October 2012 | By Pfizer
In treatment-naïve patients with advanced renal cell carcinoma...
List view / Grid view
News
VICTRELIS® (boceprevir) awarded 2012 Prix Galien USA Best Pharmaceutical Agent
17 October 2012 | By Merck
VICTRELIS® has received the Prix Galien USA Award for best pharmaceutical agent
Bristol-Myers Squibb’s YERVOY® awarded prestigious Prix Galien USA prize for best biotechnology product
17 October 2012 | By Bristol-Myers Squibb Company
Yervoy also shortlisted for Prix Galien Prize in Germany...
Biogen Idec receives notification of PDUFA date extension
17 October 2012 | By Biogen Idec
Biogen Idec announced that the U.S. FDA has extended the initial PDUFA date...
Further success for CI Precision’s dispensary management software in India
16 October 2012 | By CI Precision
CI Precision has been awarded a new contract...
Increased flexibility and choice for Tecan’s Cavro® Centris Pump
16 October 2012 | By kdm communications limited
The state-of-the-art Cavro Centris Pump from Tecan is now available...
FDA clears ACCU-CHEK Inform II
16 October 2012 | By Roche
Hospital point-of-care system for blood glucose testing with improved accuracy and wireless data transfer Next-generation system...
Novo Nordisk files for regulatory approval of turoctocog alfa for haemophilia A in the US and EU
16 October 2012 | By Novo Nordisk
Novo Nordisk announced the submission of the regulatory application for turoctocog alfa...
U.S. Food and Drug Administration approves labeling update for BARACLUDE®
15 October 2012 | By Bristol-Myers Squibb Company
Studies provide data on BARACLUDE in special populations...
Abbott’s investigational interferon-free Hepatitis C treatment regimen achieved SVR12 (observed data) rates in 99 percent of treatment-naïve
15 October 2012 | By Abbott
Initial results from "Aviator"...
AiCuris and Merck enter exclusive worldwide license agreement for investigational portfolio targeting human cytomegalovirus
15 October 2012 | By Merck
Merck and AiCuris enter into an agreement...
Amgen presents several sub-analyses at ASBMR from the ongoing open-label extension study of the pivotal Phase 3 Prolia fracture trial
14 October 2012 | By Amgen
Data from several Prolia® studies...
Merck researchers present BMD data from a Phase II study of Odanacatib
13 October 2012 | By Merck
Odanacatib significantly increased BMD following prior alendronate treatment...
Amgen appoints Cynthia Patton Senior Vice President and Chief Compliance Officer
12 October 2012 | By Amgen
Amgen has announced the appointment of Cynthia M. Patton...
New data from Phase 3 studies provide additional evidence supporting treatment effect for oral BG-12 in Multiple Sclerosis
12 October 2012 | By Biogen Idec
New data from studies evaluating oral BG-12...
